Your browser doesn't support javascript.
loading
Early Exploratory Analysis for Patient-reported Quality of Life and Dosimetric Correlates in Hypofractionated Stereotactic Body Radiation Therapy (SBRT) for Low-risk and Intermediate-risk Prostate Cancer: Interim Results from a Prospective Phase II Clinical Trial.
Iarrobino, Nick A; Gill, Beant; Sutera, Philip A; Kalash, Ronny; D' Ambrosio, David; Heron, Dwight E.
Afiliação
  • Iarrobino NA; University of Pittsburgh School of Medicine.
  • Gill B; Department of Radiation Oncology, UPMC Hillman Cancer Center, Pittsburgh, PA.
  • Sutera PA; University of Pittsburgh School of Medicine.
  • Kalash R; Department of Radiation Oncology, UPMC Hillman Cancer Center, Pittsburgh, PA.
  • D' Ambrosio D; East Coast Radiation Oncology, Toms River, NJ.
  • Heron DE; University of Pittsburgh School of Medicine.
Am J Clin Oncol ; 42(11): 856-861, 2019 11.
Article em En | MEDLINE | ID: mdl-31584457
OBJECTIVES: Given the relative novelty of stereotactic body radiation therapy as a treatment modality low-risk and intermediate-risk prostate cancer, little data exist evaluating dosimetry and its impact on patient-reported quality of life (PR-QOL) metrics. Herein, we present an interim analysis of a phase II clinical trial of PR-QOL and dosimetric correlates. METHODS: Patients with biopsy-proven low-risk or intermediate-risk prostate cancer, prostate volume ≤100 cm, and life expectancy ≥10 years were enrolled. Expanded Prostate Cancer Index Composite (EPIC) scores were tabulated by domain and evaluated in relation to dosimetry. Paired t test was performed to compare differences in scores from baseline. Minimally important differences were established using the anchor-based approach and correlations made using the χ test. RESULTS: A total of 95 patients were analyzed with a median follow-up of 18.1 months (range, 3.0 to 76.9 mo). There were no cases of acute or late grade 3+ GI or GU toxicities. Expanded Prostate Cancer Index Composite scores in urinary obstructive/irritative domain at 1 month (-4.8, P=0.03) and bowel domain at 1, 6, and 12 months (-10.8, -6.1, and -5.2) were significantly different from pretreatment, with both returning to nonsignificant differences around 24 months. Higher bladder V37Gy (≥3.35%) was associated with both late urinary incontinence and obstructive/irritative declines. Both higher rectal D5% and rectal V36Gy >0.6 cm were correlated with an enhanced proportion of patients with late minimally important difference declines. CONCLUSIONS: Higher dose volumes for the bladder and rectum predicted for poorer PR-QOL. In contrast to prostate brachytherapy data, neither prostate volume nor urethral dosimetry at this dose schedule correlated with urinary symptoms.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Qualidade de Vida / Radiocirurgia / Fracionamento da Dose de Radiação / Medidas de Resultados Relatados pelo Paciente Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Qualidade de Vida / Radiocirurgia / Fracionamento da Dose de Radiação / Medidas de Resultados Relatados pelo Paciente Idioma: En Ano de publicação: 2019 Tipo de documento: Article